Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study)

Hong-Shuai Li 1,†, Shou-Zheng Wang 1,2,†, Hai-Yan Xu 3, Xiang Yan 4,†, Jin-Yao Zhang 1, Si-Yu Lei 1, Teng Li 1, Xue-Zhi Hao 1, Tao Zhang 5, Guang-Jian Yang 6, Li-Qiang Zhou 1, Peng Liu 1, Yu-Ying Wang 4, Xing-Sheng Hu 1, Pu-Yuan Xing 1,* and Yan Wang 1,*†

1 Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2 Department of Medical Oncology, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing 101149, China
3 Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
4 Department of Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing 100000, China
5 Department of Radiotherapy, National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100000, China
6 Department of Respiratory Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Ji’nan 250000, China

* Correspondence: xingyuant@cicams.ac.cn (P.-Y.X.); wangyanyifu@163.com (Y.W.)
† These authors contributed equally to this work.

Abstract: Afatinib has been approved for patients with lung cancer carrying uncommon epidermal growth factor receptor gene (EGFR) mutations. Dacomitinib, another second-generation inhibitor, has also shown promising potential for these mutations. This is the first and largest comparative study on second-generation inhibitors in patients with uncommon EGFR mutations to date. We found that dacomitinib demonstrated a more favorable activity with manageable toxicity compared with afatinib, which provided more evidence for dacomitinib application in this setting.

Simple Summary: Afatinib has been approved for patients with lung cancer carrying uncommon epidermal growth factor receptor gene (EGFR) mutations. Dacomitinib, another second-generation tyrosine kinase inhibitor, has also shown promising potential for these mutations. However, no comparative study has been conducted. (2) Methods: Two cohorts were employed: the AFANDA cohort, an ambispective cohort including 121 patients with uncommon EGFR mutations admitted to two tertiary hospitals in China, and an external validation afatinib cohort (ex-AC), extracted from the Afatinib Uncommon EGFR Mutations Database (N = 1140). The AFANDA cohort was divided into an afatinib cohort (AC) and a dacomitinib cohort (DC) for internal exploration. Objective response rate (ORR), progression-free survival (PFS), and adverse events (AEs) were assessed for comparison. Progression patterns and resistance mechanisms were explored. (3) Results: In total, 286 patients with advanced NSCLC carrying uncommon EGFR mutations treated with afatinib or dacomitinib were enrolled, including 79 in the AFANDA cohort (44 in the DC, 35 in the AC) and 207 in the ex-AC. In internal exploration, the ORR of the DC was significantly higher than that of the AC (60.5 vs. 26.7%, p = 0.008), but there was no significant difference in median PFS between the DC and the AC (12.0 months vs. 10.0 months, p = 0.305). Multivariate analysis confirmed an independent favorable effect of dacomitinib on PFS (hazard ratio (HR), 1.909; p = 0.047). In external validation, multivariate analysis confirmed the independent prognostic role of dacomitinib in PFS (HR, 1.953; p = 0.029). Propensity score matching analysis confirmed the superiority of dacomitinib over afatinib in terms of PFS in both univariate and multivariate analyses.
Toxicity profiling analysis suggested more G1 ($p = 0.006$), but fewer G3 ($p = 0.036$) AEs in the DC than in the AC. Progression patterns revealed that the incidence of intracranial progression in the AC was significantly higher than that in the DC (50 vs. 21.1%, $p = 0.002$). Drug resistance analysis indicated no significant difference in the occurrence of T790M between the AC and the DC (11.8 vs. 15.4%, $p = 0.772$). (4) Conclusions: Compared with afatinib, dacomitinib demonstrated a more favorable activity with manageable toxicity and different progression patterns in patients with NSCLC carrying uncommon EGFR mutations.

**Keywords:** non-small cell lung cancer; dacomitinib; afatinib; uncommon EGFR mutations; efficacy; safety; progression patterns; resistance

1. **Background**

Lung cancer remains one of the most prevalent and deadly cancers worldwide [1,2]. Targeted therapies, represented by epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), have greatly improved the quality of life and prognosis of patients with non-small cell lung cancer (NSCLC) [2]. Patients carrying common EGFR mutations (including in-frame deletion mutations in exon 19 (19del) and missense mutations in exon 21 (L858R)) significantly benefit from EGFR-TKIs; however, because of the high heterogeneity of uncommon EGFR mutations (defined as mutations other than classical mutations), patients carrying such mutations differ dramatically in their sensitivity to TKIs [3–7]. In general, patients carrying uncommon EGFR mutations are less sensitive to TKIs than those harboring classical mutations and tend to have an unfavorable prognosis [8].

Studies by Yang et al. have demonstrated the excellent efficacy of afatinib in patients with NSCLC carrying major uncommon mutations (including G719X, S768I, and L861Q) [9,10]. Afatinib has been approved by the Food and Drug Administration (FDA) and is endorsed by the National Comprehensive Cancer Network guidelines as the preferred first-line treatment in this subset of patients. Dacomitinib, another highly selective, irreversible second-generation (2G) EGFR-TKI, has been approved as a first-line treatment in patients with NSCLC carrying classical EGFR mutations as it significantly improved progression-free survival (PFS) as compared with gefitinib in the ARCHER 1050 study [11]. In this context, it is desirable to assess the therapeutic potential of dacomitinib in patients carrying uncommon mutations. In fact, dacomitinib has shown potential for the treatment of NSCLC in patients harboring uncommon mutations [12–17]. We previously demonstrated the efficacy of dacomitinib in patients with NSCLC carrying uncommon EGFR mutations in first-line and later-line settings [16–18].

Based on our previous findings, in this study, we compared dacomitinib and afatinib in terms of efficacy, safety, progression patterns, and resistance mechanisms in patients with NSCLC carrying uncommon EGFR mutations with the aim of obtaining valuable evidence for clinical decision making.

2. **Methods**

2.1. **Study Design and Data Resources**

This was a comparative cohort study in two centers in China. Patients with advanced or recurrent NSCLC carrying uncommon EGFR mutations treated with afatinib or dacomitinib were eligible for evaluation. Two cohorts were employed in the current study. The AFANDA cohort, an ambispective cohort, was used for internal exploration. It included 121 patients carrying uncommon EGFR mutations who received afatinib or dacomitinib between 1 January 2017 and 15 April 2022 at two tertiary hospitals in China, namely, the Chinese PLA Hospital and the Chinese National Cancer Center. The external validation afatinib cohort (ex-AC) was extracted from the publicly available Aflatinib Uncommon EGFR Mutations Database (https://www.uncommonegfrmutations.com/) (last extraction date: 20 June 2022), which includes 1140 patients harboring uncommon EGFR mutations.
treated with afatinib retrieved from publications [10,19–26]. The AFANDA cohort was divided into an afatinib cohort (AC) and a dacomitinib cohort (DC) for internal exploration, and the ex-AC was employed for external validation.

2.2. Patient Selection Criteria

The patient selection criteria were as follows. For the AFANDA cohort: (1) patients with histologically or cytologically confirmed diagnosis of advanced or recurrent NSCLC; (2) patients harboring uncommon EGFR mutations (other than T790M, exon 20 insertions (EX20ins), and compound 19del/L858R); (3) patients from whom tumor tissue or cell-free DNA from humoral samples (including plasma, cerebrospinal fluid, and pleural effusion) before dacomitinib/afatinib administration were analyzed utilizing next-generation sequencing (NGS) or amplification refractory mutation system PCR at the above two centers or at a CAP-accredited institution; (4) patients who received dacomitinib or afatinib monotherapy; and (5) patients whose survival data were complete. For the ex-AC: (1) patients from clinical trials/clinical studies other than case studies/case series and the compassionate-use program (CUP)/expanded-access program (EAP); (2) patients harboring uncommon EGFR mutations (other than T790M, EX20ins, and compound 19del/L858R); and (3) patients whose survival data were complete.

2.3. Treatment and Efficacy/Toxicity Evaluation

All enrolled patients received single-agent dacomitinib or afatinib. The dacomitinib or afatinib dosage was determined according to the patient’s comorbidities, weight, and physical status. The objective response, including complete response (CR) and partial response (PR), and disease control, including CR, PR, and stable disease (SD), were judged according to the RECIST (version 1.1) guideline. Toxicity was assessed according to the CTCAE 5.0 criteria.

2.4. Exploration of Resistance Mechanisms

Cell-free DNA from humoral samples (including plasma, cerebrospinal fluid, and pleural effusion) after dacomitinib/afatinib resistance were analyzed utilizing next-generation sequencing (NGS) using an ultra-deep (20,000 ×) 168-gene panel named LungPlasma (Burning Rock Biotech, Guangzhou, China). The analyses were performed at the above two centers or at a CAP-accredited institution (commercially, >200-gene panel).

2.5. Statistical Analysis

The study cutoff date was 15 May 2022. PFS was defined as the interval from dacomitinib or afatinib administration to disease progression or death due to any cause. Patients lost to follow-up were reviewed, and the last determinable survival time was taken as the end of follow-up.

Categorical data are reported as numbers and percentages and were analyzed using the chi-square test. Survival analysis was conducted using the Kaplan–Meier method. Univariate and multivariate Cox proportional hazards models were utilized to assess the associations between variables and PFS. The multivariate model included variables that were found to be significant in the univariate analyses and variables that were considered clinically significant.

Propensity score matching (PSM), applying a caliper width of 0.2 of the standard deviation, was conducted to produce matched groups of the DC and the ex-AC. The analysis was based on age, sex, smoking status, treatment history, brain metastases status, mutation category, exon category, and compound mutation status. SPSS software (version 23.0, IBM Corporation, Armonk, NY, USA) was employed to conduct the PSM analysis [27,28]. All statistical analyses were conducted using R software (version 4.0.0, R Foundation). A two-sided p-value < 0.05 was considered statistically significant.
3. Results

A flow chart of patient selection is shown in Figure 1. In total, 286 patients were enrolled, including 79 in the AFANDA cohort (44 in the DC, 35 in the AC) and 207 in the ex-AC [9,10,19–26]. The median follow-up time was 12.4 months (range: 0.8–51.2 months) in the AFANDA cohort and 32.2 months (0–70.8 months) in the ex-AC.

Figure 1. Flow chart of patient selection. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; EX20ins, exon 20 insertion mutations; DC, dacomitinib cohort; AC, afatinib cohort; ex-AC, external afatinib cohort; CUP/EAP, compassionate-use program/expanded-access program.

3.1. Baseline Characteristics in the DC and the AC

The clinical, pathological, and molecular characteristics of patients in the DC and the AC are provided in Table 1. All characteristics were balanced and comparable between the two cohorts. More than 65% of the patients were female and never-smokers, and more than 25% had brain metastases. Most patients in both cohorts had a performance status (Eastern Cooperative Oncology Group (ECOG) PS) of 1. G719X was the most common mutation in both cohorts, followed by L861Q and S768I in the DC and S768I and L861Q in the AC. Uncommon mutations most frequently involved exon 18. The detailed mutation landscapes of the DC and the AC are shown in Figure S1a,b. Dacomitinib and afatinib were administrated as the first-line therapy in more than 60% of patients.
Table 1. Baseline characteristics of the DC and the AC (N = 79).

| Characteristic                  | DC (N = 44) | AC (N = 35) | p Value |
|--------------------------------|-------------|-------------|---------|
| Age                            |             |             | 0.859   |
| ≤60                            | 21 (47.7)   | 16 (45.7)   |         |
| >60                            | 23 (52.3)   | 19 (54.3)   |         |
| Sex                            |             |             | 0.367   |
| Female                         | 33 (75.0)   | 23 (65.7)   |         |
| Male                           | 11 (25.0)   | 12 (34.3)   |         |
| Smoking history                |             |             | 0.802   |
| No                             | 29 (65.9)   | 24 (68.6)   |         |
| Yes                            | 15 (34.1)   | 11 (31.4)   |         |
| Histology                      |             |             | 1.000   |
| Adenocarcinoma                 | 43 (97.7)   | 35 (100)    |         |
| Adenosquamous carcinoma        | 1 (2.3)     | 0           |         |
| Stage                          |             |             | 0.286   |
| Relapsed                       | 12 (27.3)   | 6 (17.1)    |         |
| IV                             | 32 (72.7)   | 29 (82.9)   |         |
| Brain metastases               |             |             | 0.125   |
| No                             | 24 (54.5)   | 25 (71.4)   |         |
| Yes                            | 20 (45.5)   | 10 (28.6)   |         |
| Total tumor burden             |             |             | 0.758   |
| <3 metastatic organs           | 34 (77.3)   | 26 (74.3)   |         |
| ≥3 metastatic organs           | 10 (22.7)   | 9 (25.7)    |         |
| ECOG PS                        |             |             | 0.683   |
| 0                              | 11 (25.0)   | 6 (17.1)    |         |
| 1                              | 28 (63.6)   | 24 (68.6)   |         |
| 2                              | 5 (11.4)    | 5 (14.3)    |         |
| Application line               | Median (range): 1 (1–6) | Median (range): 1 (1–5) | 0.475 |
| 1                              | 27 (61.4)   | 26 (74.3)   |         |
| 2                              | 9 (20.5)    | 5 (14.3)    |         |
| ≥3                             | 8 (18.2)    | 4 (11.4)    |         |
| Mutation category *            |             |             | 0.396   |
| G719X                          | 24 (54.5)   | 23 (65.7)   |         |
| G719X                          | 9 (20.5)    | 10 (28.6)   |         |
| G719X + S768I                  | 9 (20.5)    | 11 (31.4)   |         |
| G719X + L861X                  | 2 (4.5)     | 0           |         |
| G719X + others                 | 4 (9.1)     | 2 (5.7)     |         |
| S768I                          | 9 (20.5)    | 12 (34.3)   |         |
| S768I + G719X                  | 9 (20.5)    | 11 (31.4)   |         |
| S768I + others                 | 0 (0)       | 1 (2.9)     |         |
| L861X                          | 12 (27.3)   | 5 (14.3)    |         |
Table 1. Cont.

| Characteristic          | DC (N = 44) | AC (N = 35) | p Value |
|-------------------------|-------------|-------------|---------|
| L861X                   | 9 (20.5)    | 3 (8.6)     |         |
| L861X + G719X           | 2 (4.5)     | 1 (2.9)     |         |
| L861X + others          | 1 (2.3)     | 1 (2.9)     |         |
| Others                  | 15 (34.1)   | 11 (31.4)   |         |

**Exon category**: 
| Exon | DC (N = 44) | AC (N = 35) | p Value |
|------|-------------|-------------|---------|
| 18   | 27 (61.4)   | 25 (71.4)   | 0.299   |
| 19   | 4 (9.1)     | 3 (8.6)     |         |
| 20   | 9 (20.5)    | 13 (37.1)   |         |
| 21   | 13 (29.5)   | 6 (17.1)    |         |
| Others | 6 (13.6)   | 1 (2.9)     |         |

**Compound mutations**: 
|       | DC (N = 44) | AC (N = 35) | p Value |
|-------|-------------|-------------|---------|
| No    | 28 (63.6)   | 18 (51.4)   | 0.274   |
| Yes   | 16 (36.4)   | 17 (48.6)   |         |

Data are shown as n (%). ECOG PS, Eastern Cooperative Oncology Group performance status; DC, dacomitinib cohort; AC, afatinib cohort. * Uncommon mutation categories overlap with compound mutations, so each patient might belong to more than one group.

3.2. Efficacy Evaluation, Survival Analysis, and Subgroup Analysis in the DC and the AC

The objective response rate (ORR) was significantly higher in the DC than in the AC (60.5 vs. 26.7%, \( p = 0.008 \)) (Figure 2a). The Kaplan–Meier analysis revealed a longer, albeit not significantly longer, median PFS (mPFS) in the DC than in the AC (12.0 months vs. 10.0 months, \( p = 0.305 \)) (Figure 2b). The ORRs of subtypes, including mutation category (Figure 2c) and exon category (Figure 2d), were generally higher in the DC than in the AC, especially “other mutation types” in the mutation category (66.7 vs. 9.1%, \( p = 0.003 \)). Subgroup analysis suggested that patients in the AC tended to have a higher risk of progression than those in the DC in most subgroups, particularly for other mutation types in the mutation category (HR, 2.844; \( p = 0.040 \)) (Figure 2e).

3.3. Univariate and Multivariate Analyses in the Pooled DC and AC

To determine the effects of the different interventions and characteristics on PFS, we pooled the DC and the AC and then conducted univariate and multivariate analyses. The univariate analysis revealed that PFS was significantly associated with brain metastases (\( p = 0.004 \)), tumor burden (\( p < 0.001 \)), ECOG PS (\( p < 0.001 \)), and application line (\( p = 0.018 \)) (Table 2). The multivariate analysis confirmed an independent favorable prognostic role of dacomitinib in PFS (DC vs. AC: HR, 1.909; 95% CI, 1.009–3.610; \( p = 0.047 \), and ECOG PS (\( p < 0.001 \)) and application line (\( p = 0.043 \)) were also independent factors in the final regression model (Table 2).
Figure 2. Comprehensive comparison between the DC and the AC. Stacked histogram of treatment responses (a), Kaplan-Meier curves (b), ORRs of different mutation categories (c), ORRs of different exon categories (d), and subgroup analysis of PFS (e) of the DC and the AC. ORR, objective response rate; PFS, progression-free survival; DC, dacomitinib cohort; AC, afatinib cohort; PR, partial response; SD, stable disease; PD, progressive disease; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status. * Uncommon mutation categories overlap with compound mutations, so each patient might belong to more than one group.
Table 2. Univariate and multivariate analyses of PFS in the pooled cohort of the DC and the AC (N = 79).

| Characteristic                  | N     | Univariate Analysis | Multivariate Analysis |
|--------------------------------|-------|---------------------|-----------------------|
|                                |       | Median (Months)     | p Value   | HR     | 95% CI | p Value |
| Intervention                   | 0.305 |                     |           |        |        |         |
| Dacomitinib/Afatinib           | 44/35 | 12.0/10.0           | 0.047     | 1.909  | 1.009–3.610 |
| Smoking history                | 0.914 |                     |           |        |        |         |
| No/Yes                         | 53/26 | 11.0/11.5           | 0.184     | 1.569  | 0.808–3.047 |
| Brain metastases               | 0.004 |                     |           |        |        |         |
| No/Yes                         | 0.096 |                     |           |        |        |         |
| Total tumor burden             | <0.001|                     |           |        |        |         |
| <3/≥3 metastatic organs       | 1.351 |                     |           |        |        |         |
| ECOG PS                        | <0.001|                     |           |        |        |         |
| 0                              | 17    | 28.6                | <0.001    | -      | <0.001 |
| 1                              | 52    | 10.1                |           | 6.470  | 1.871–22.381 | 0.003 |
| 2                              | 10    | 4.3                 |           | 30.327 | 6.915–133.005 | <0.001 |
| Application line               | 0.018 |                     |           | 2.16   | 0.985–4.737 | 0.055 |
| 1                              | 53    | 12.9                | 0.043     | 2.55   | 1.073–6.059 | 0.034 |
| 2                              | 14    | 8.1                 |           |        |        |         |
| ≥3                             | 12    | 6.5                 |           |        |        |         |
| Mutation category *            | 0.619 |                     |           | 1.958  | 0.756–5.071 | 0.166 |
| G719X                          | 19    | 10.3                |           |        |        |         |
| L861X                          | 12    | 10.0                |           | 3.725  | 1.193–11.627 | 0.024 |
| Others                         | 16    | 12.4                |           | 1.958  | 0.756–5.071 | 0.166 |
| Compound mutations             | 32    | 11.0                |           | 1.796  | 0.840–3.838 | 0.131 |

Data are shown as n (%). PFS, progression-free survival; ECOG PS, Eastern Cooperative Oncology Group performance status; DC, dacomitinib cohort; AC, afatinib cohort. Set variables before “/” as reference. * To meet the requirements of multivariate analysis, all patients were classified separately without repeated grouping. The S768I sub-category is not shown because there were no cases with single S768I in the combined cohort.

3.4. Toxicity Analysis in the DC and the AC

The DC and the AC shared a spectrum of AEs, which mainly included rash, diarrhea, oral mucositis, paronychia, and dry skin (Table 3). The main AEs in the DC were rash (90.9%), diarrhea (77.3%), and oral mucositis (61.4%), whereas in the AC, the main AEs were diarrhea (62.9%), oral mucositis (57.1%), and rash (51.4%). The proportion of G1 AEs in the DC was significantly higher than that in the AC (p = 0.006), whereas the proportion of G3 diarrhea in the AC was significantly higher than that in the DC (p = 0.036).

3.5. External Validation in the DC and the ex-AC

The clinical, pathological, and molecular characteristics of patients in the DC and the ex-AC are provided in Table 4. Most characteristics were significantly different between the two cohorts. The detailed mutation landscape of the ex-AC is shown in Figure S1c.
Table 3. Treatment-emergent AEs in the pooled cohort of the DC and the AC (N = 79).

| AE          | DC (N = 44) | AC (N = 207) | p Value | DC (N = 28) | AC (N = 48) | p Value | DC (N = 28) | AC (N = 48) | p Value |
|-------------|-------------|--------------|---------|-------------|--------------|---------|-------------|--------------|---------|
| Rash        | 22 (50.0)   | 15 (42.9)    | 0.006   | 16 (36.4)   | 3 (8.6)      | 0.142   | 2 (4.5)     | 0            | 0.036   |
| Diarrhea    | 25 (56.8)   | 6 (17.1)     |         | 7 (15.9)    | 8 (22.9)     |         | 2 (4.5)     | 8 (22.9)     |         |
| Oral mucositis | 16 (36.4) | 12 (34.3)    |         | 9 (20.5)    | 8 (22.9)     |         | 2 (4.5)     | 0            |         |
| Paronychia  | 7 (15.9)    | 11 (31.4)    |         | 6 (13.6)    | 2 (5.7)      |         | 0           | 0            |         |
| Dry skin    | 12 (27.3)   | 1 (2.9)      |         | 5 (11.4)    | 1 (2.9)      |         | 1 (2.3)     | 0            |         |
| Others      | 4 (9.1)     | 0            |         | 1 (2.3)     | 0            |         | 0           | 0            |         |

Data are presented as n (%). DC, dacomitinib cohort; AC, afatinib cohort; AE, adverse event. There were no grade 4–5 treatment-emergent AEs.

Table 4. Baseline characteristics of the DC and the ex-AC before and after PSM (1:2 matching).

| Characteristic | Before PSM | After PSM | p Value | Before PSM | After PSM | p Value | Before PSM | After PSM | p Value |
|---------------|------------|-----------|---------|------------|-----------|---------|------------|-----------|---------|
| Age <60       | 21 (47.7)  | 76 (36.7) | 0.173   | 11 (39.3)  | 20 (41.7) | 0.839   |
| Age ≥60       | 23 (52.3)  | 131 (63.3)|         | 17 (60.7)  | 28 (58.3) |         |
| Sex Female    | 33 (75.0)  | 107 (51.7)| 0.005   | 20 (71.4)  | 29 (60.4) | 0.333   |
| Sex Male      | 11 (25.0)  | 100 (48.3)|         | 8 (28.6)   | 19 (39.6) |         |
| Smoking history No | 29 (65.9) | 74 (35.7) | <0.001  | 18 (64.3)  | 27 (56.3) | 0.150   |
| Smoking history Yes | 15 (34.1) | 88 (42.5)|         | 10 (35.7)  | 15 (31.3) |         |
| Unknown       | 0          | 45 (21.7) |         | 0          | 6 (12.5)  |         |
| Brain metastases No | 24 (54.5) | 186 (89.9)| <0.001  | 22 (78.6)  | 38 (79.2) | 0.951   |
| Brain metastases Yes | 20 (45.5) | 21 (10.1)|         | 6 (21.4)   | 10 (20.8) |         |
| Treatment history |        |          | <0.001  |            |            | 0.615   |
| TKI-naïve     | 27 (61.4)  | 201 (97.1)|         | 24 (85.7)  | 43 (89.6) |         |
| TKI-pretreated | 17 (38.6) | 6 (2.9)   |         | 4 (14.3)   | 5 (10.4)  |         |
| Mutation category * G719X | 9 (20.5) | 82 (39.6) | 0.001   | 6 (21.4)   | 7 (14.6)  | 0.535   |
| L861X         | 9 (20.5)   | 57 (27.5)  |         | 6 (21.4)   | 13 (27.1) |         |
| S768I         | 0          | 10 (4.8)   |         | 0          | 3 (6.3)   |         |
| Others        | 10 (22.7)  | 15 (7.2)   |         | 7 (25.0)   | 8 (16.7)  |         |
| Compound mutations | 16 (36.4) | 43 (20.8) |         | 9 (32.1)   | 17 (35.4) |         |
No significant differences were observed regarding the ORRs (Figure 3a) and the mPFS (Figure 3b) between the DC and the ex-AC (ORRs: 60.5 vs. 51.1%, \( p = 0.472 \); mPFS: 12.0 months vs. 10.4 months, \( p = 0.325 \)). The ORRs of subtypes, including mutation category (Figure 3c) and exon category (Figure 3d), did not significantly differ. Subgroup analysis suggested that patients in the ex-AC had a greater risk of progression than those in the DC in most subgroups, particularly in the no brain metastases (HR, 2.258; \( p = 0.036 \)) and TKI-naïve (HR, 2.415; \( p = 0.023 \)) subgroups (Figure 3e).

Univariate analysis of the pooled DC and ex-AC indicated that sex (\( p = 0.035 \)) and treatment history (\( p = 0.033 \)) were significantly associated with PFS. To reduce the confounding effects of imbalances in the baseline characteristics, a multivariate analysis was subsequently conducted, and this confirmed the independent favorable prognostic role of dacomitinib in PFS (DC vs. ex-AC: HR, 1.953; 95% CI, 1.071–3.563; \( p = 0.029 \)) (Table 5).
Cancers 2022, 14, x FOR PEER REVIEW 11 of 20

Figure 3. Comprehensive comparison between the DC and the ex-AC before PSM. Stacked histogram of treatment responses (a), Kaplan-Meier curves (b), ORRs of different mutation categories (c), ORRs of different exon categories (d), and subgroup analysis of PFS (e) of the DC and the ex-AC before PSM. ORR, objective response rate; PFS, progression-free survival; DC, dacomitinib cohort; AC, afatinib cohort; ex-AC, external afatinib cohort; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; HR, hazard ratio; CI, confidence interval; TKI, tyrosine kinase inhibitor; PSM, propensity score matching. * Uncommon mutation categories overlap with compound mutations, so each patient might belong to more than one group.
Figure 4. Comprehensive comparison between the DC and the ex-AC after PSM. Stacked histogram of treatment responses (a), Kaplan-Meier curves (b), ORRs of different mutation categories (c), ORRs of different exon categories (d), and subgroup analysis of PFS (e) of the DC and the ex-AC after PSM. ORR, objective response rate; PFS, progression-free survival; DC, dacomitinib cohort; AC, afatinib cohort; ex-AC, external afatinib cohort; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; HR, hazard ratio; CI, confidence interval; TKI, tyrosine kinase inhibitor; PSM, propensity score matching. * Uncommon mutation categories overlap with compound mutations, so each patient might belong to more than one group. Since there were no cases with others in the ex-AC, the forest plot was not drawn.
Table 5. Univariate and multivariate analyses of PFS in the pooled cohort of the DC and the ex-AC. (N = 251).

| Characteristic        | N   | Univariate Analysis | Multivariate Analysis |
|-----------------------|-----|---------------------|-----------------------|
|                       |     | Median (Months)     | p Value               |
| Intervention          |     |                     |                       |
| Dacomitinib/Afatinib  | 44/207 | 12.0/10.4          | 1.953                 |
|                       |     |                     | 1.071–3.563           |
| Age                   |     | 0.569               |                       |
| <60/ ≥60              | 97/154 | 11.1/10.5           | 1.098                 |
|                       |     |                     | 0.806–1.498           |
| Sex                   |     | 0.035               |                       |
| Female/Male           | 140/111 | 12.0/8.2           | 1.397                 |
|                       |     |                     | 0.991–1.97            |
| Smoking history       |     | 0.528               |                       |
| No                    | 103  | 12.5                | Reference             |
| Yes                   | 103  | 8.4                 | 1.054                 |
| Unknown               | 45   | 10.5                | 1.063                 |
| Brain metastases      |     | 0.180               |                       |
| No/Yes                | 210/41 | 10.6/10.1          | 1.279                 |
|                       |     |                     | 0.824–1.985           |
| Treatment history     |     | 0.033               | 0.003                 |
| TKI-naïve/pretreated  | 228/23 | 10.7/6.7           | 2.675                 |
|                       |     |                     | 1.402–5.101           |
| Mutation category *   |     | 0.059               | 0.040                 |
| G719X                 | 91   | 10.3                | Reference             |
|                       |     |                     | -                     |
| L861X                 | 66   | 7.4                 | 1.495                 |
|                       |     |                     | 1.041–2.147           |
| S768I                 | 10   | 20.7                | 0.507                 |
|                       |     |                     | 0.219–1.173           |
| Others                | 25   | 10.7                | 1.320                 |
|                       |     |                     | 0.755–2.308           |
| Compound mutations    | 59   | 14.2                | 0.973                 |
|                       |     |                     | 0.651–1.453           |

Data are shown as n (%). PFS, progression-free survival; DC, dacomitinib cohort; ex-AC, external afatinib cohort; TKI, tyrosine kinase inhibitor. Set variables before “/” as reference. * To meet the requirements of multivariate analysis, all patients were classified separately without repeated grouping.

Univariate analysis of the pooled DC and ex-AC indicated that only dacomitinib intervention (p = 0.033) was significantly associated with PFS, and multivariate analysis confirmed the independent favorable prognostic role of dacomitinib in PFS (DC vs. ex-AC: HR, 3.030; 95% CI, 1.304–7.042; p = 0.010) (Table S1).

3.7. Progression Patterns, Resistance Mechanisms, and Subsequent Therapies

Analysis of the progression patterns of patients (N = 45) (Figure 5a,b) revealed a significantly higher incidence of intracranial progression in the AC than in the DC (50% vs. 21.1%, p = 0.002) (Table S2). Liquid biopsy-based NGS data were available for 30 patients who developed drug resistance. Drug resistance analysis indicated no significant difference in the occurrence of secondary T790M between the AC and the DC (11.8 vs. 15.4%, p = 0.772) (Figure 5c) (Table S3). The top three off-target mutations were identified as TP53 (53%), LRP1B (13%), and PTEN (13%) in the pooled cohort, as TP53 (46.2%), PTEN (38.5%), and PKHD1 (38.5%) in the DC, and as TP53 (58.8%), LRP1B (17.6%), and CHD8 (17.6%) in the AC (Figure 5c). The bridging therapies used after the onset of dacomitinib and afatinib resistance in the DC and the AC, respectively, are summarized in Figure 5d,e. Combined application of dacomitinib and an anti-angiogenic agent (AAA) (bevacizumab or anlotinib) was the most frequently used (25%) in the DC after drug resistance, whereas afatinib + AAA ± brain radiotherapy was the most frequently used (24%) in the AC. The proportion of patients receiving local interventions (including brain radiotherapy and local interventional therapies) was significantly lower in the DC than in the AC (10 vs. 56%, p = 0.001) (Table S4).
Figure 5. Progression patterns (a–b), resistance mechanisms (c), and bridging therapies (d–e) in the DC and the AC. AAA, anti-angiogenic agent; RT, radiotherapy; Chemo, chemotherapy; Daco, dacomitinib; Osi, osimertinib; LIT, local intervention therapy; PD-1, programmed cell death protein 1; amp, amplification; DC, dacomitinib cohort; AC, afatinib cohort. * Uncommon EGFR mutations other than major ones, T790M, and EX20ins. The non-EGFR mutations presented were all identified as resistance mechanisms rather than as present in the original tumor.

4. Discussion

In the current study, we tentatively compared 2G TKIs in patients with NSCLC carrying uncommon EGFR mutations with the aim of obtaining valuable evidence for clinical reference. The findings of the internal cohort exploration and external cohort validation indicated that dacomitinib had an efficacy advantage over afatinib in patients with NSCLC carrying uncommon EGFR mutations with a manageable safety profile, which warrants further clinical exploration and confirmation. In addition, we provided data on progression patterns and resistance mechanisms in patients treated with 2G TKIs. To the
best of our knowledge, this is the first and largest comparative study to date on 2G TKIs in patients with NSCLC carrying uncommon EGFR mutations.

Previous evidence has demonstrated that, compared with 1G TKIs, the 2G TKI afatinib has a more favorable effect on PFS in patients with NSCLC harboring uncommon EGFR mutations (afatinib vs. gefitinib vs. erlotinib: 10.5 months vs. 3.0 months vs. 0.9 months, \( p = 0.013 \)) [29]. A post-hoc analysis conducted by Yang et al. revealed that for patients carrying the major uncommon mutations G719X, S768I, and L861Q, the ORRs and mPFS reached 77.8, 100, and 56.3% and 13.8 months, 14.7 months, and 8.2 months, respectively [9]. Therefore, in 2018, afatinib was approved by the FDA for patients with NSCLC harboring major uncommon mutations. The 3G TKI osimertinib has also been shown to be efficacious in patients harboring G719X, S768I, and L861Q, with ORRs of 53, 38, and 78% and an mPFS of 8.2 months, 12.3 months, and 15.2 months, respectively, in the KCSG-LU15-09 study [30].

At present, data on the treatment of uncommon EGFR mutations with dacomitinib are limited, and most are from case reports and small retrospective clinical studies. Previously published studies in patients with NSCLC carrying uncommon EGFR mutations treated with dacomitinib are summarized in Table S5.

In our previous studies, we successively demonstrated the promising activity of dacomitinib in patients with NSCLC carrying uncommon EGFR mutations in first-line and later-line settings and the manageable safety profile of dacomitinib [16–18]. In the first-line setting [17], dacomitinib achieved an ORR of 72.2% and a disease control rate of 100% in patients carrying major uncommon EGFR mutations, and the mPFS and overall survival were not reached. Specifically, the ORRs in patients harboring G719X, L861Q, and S768I were 66.7%, 50%, and 100%, respectively, and the mPFS was not reached in any of the three mutation groups, which results were in line with the findings of the post-hoc analysis of afatinib in the LUX-Lung series of trials [9]. We included not only the major uncommon EGFR mutations, but also other uncommon mutations (besides T790M, EX20ins, and compound 19del/L858R) in the current study. In this setting, dacomitinib obtained an ORR of 60.5%, a disease control rate of 90.7%, and an mPFS of 12.0 months. Specifically, in patients carrying G719X, L861Q, S768I, and other uncommon mutations, the ORRs were 62.5, 54.5, 66.7, and 66.7% and the mPFS was 12 months, unreached, 6.5 months, and 12.5 months, respectively. This suggests that dacomitinib also has therapeutic potential for non-major uncommon EGFR mutations [14,16,31,32].

The secondary T790M mutation rate in the patients in our study (13%) was substantially lower than those reported in patients harboring classical mutations (40.7–64.3%) [33,34], which result was consistent with the findings reported by Wu et al. [34] and Lin et al. [35]. In the study by Wu et al., patients with uncommon EGFR mutations receiving afatinib had a lower secondary T790M mutation rate than those harboring classical mutations (64.3% for 19del, 45.5% for L858R, and only 16.7% for uncommon EGFR mutations, \( p = 0.142 \)) [34]. The study by Lin et al. revealed that an uncommon EGFR mutation was a negative independent indicator for secondary T790M mutation (adjusted odds ratio 0.14, 95% CI, 0.02–0.97; compared with 19del, \( p = 0.047 \)). Furthermore, we did not observe a significant difference in the incidence of secondary T790M between the DC and the AC. However, considering the small cohort size in this study, a firm conclusion cannot be drawn. In the context of uncommon mutations, the efficacy of sequential osimertinib after 2G TKI resistance development remains to be further explored.

Studies have demonstrated that dacomitinib has a potent efficacy in patients with NSCLC carrying brain metastases [36,37], and this has been specifically confirmed in patients with uncommon EGFR mutations [17]. In line herewith, we found a significantly lower incidence of intracranial progression in the DC than in the AC (21.1 vs. 50%, \( p = 0.002 \)). Nevertheless, we did not observe a PFS advantage of dacomitinib over afatinib in patients with or without brain metastases in subgroup analyses after PSM. We considered that this may be due to the small number of patients in the DC.

As pan-HER inhibitors, dacomitinib and afatinib share a spectrum of AEs, which mainly involve the skin and mucosa of the digestive tract [9,11,38]. In the ARCHER
1050 study, dacomitinib dose reductions were required in 66% of the patients because of intolerable AEs, and the most frequent AEs were diarrhea (86%), paronychia (61%), and rash (49%) [11]. We determined the dacomitinib dosage according to the patient’s comorbidities, weight, and physical status [16]. No patient required treatment cessation due to serious AEs, and only 15.9% (7/44) of the patients requested a dosage adjustment because of unbearable AEs. In this study, while the proportion of G1 AEs was significantly higher in the DC than in the AC (p = 0.006), the proportion of G3 diarrhea was significantly lower in the DC than in the AC (p = 0.036).

This study had several limitations. First, the AC and the DC used for internal exploration were small in scale relative to the ex-AC and came from only two hospitals within China, which may have led to selection bias. Second, the number of patients used to explore resistance mechanisms was too small, rendering the conclusions of the comparison between dacomitinib and afatinib underpowered. Considering the difficulty of conducting randomized, controlled clinical trials to study uncommon mutations, well-designed research is warranted to further clarify the optimal dosing of afatinib and dacomitinib, resistance mechanisms, and bridging issues of 2G TKIs with osimertinib, and we intend to collect more data to address these research questions in the future.

5. Conclusions

Dacomitinib demonstrated a more favorable efficacy than afatinib in terms of PFS and showed a manageable toxicity profile in patients with NSCLC carrying uncommon EGFR mutations. Differences in progression patterns and subsequent salvage therapy patterns were observed between the patients receiving dacomitinib and afatinib. The resistance mechanisms of 2G TKIs in this context remain to be explored.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers14215307/s1, Table S1: Univariate and multivariate analyses of PFS in the combined cohort of DC and ex-AC after PSM (N = 76); Table S2: Progression patterns of DC and AC; Table S3: Secondary T790M mutation detected after progression in DC and AC; Table S4: Secondary T790M mutation detected after progression in DC and AC; Table S5: A summary of published cases with NSCLC harboring uncommon EGFR mutations treated with dacomitinib; Figure S1: The mutation landscape of the three cohorts (DC, AC, and ex-AC) in this study. DC, dacomitinib cohort; AC, afatinib cohort; ex-AC, external afatinib cohort; Figure S2: Balance analyses between DC and ex-AC after PSM. DC, dacomitinib cohort; ex-AC, external afatinib cohort; TKI, tyrosine kinase inhibitor; PSM, propensity score matching. (References [39–43] are cited in the Supplementary Materials).

Author Contributions: Conceptualization, H.-S.L., P.-Y.X. and Y.W.; methodology, H.-S.L., S.-Z.W., P.-Y.X. and Y.W.; validation, H.-S.L., S.-Z.W., H.-Y.X., X.Y., J.-Y.Z., T.L., S.-Y.L., P.-Y.X., X.-Z.H., T.Z., G.-J.Y., L.-Q.Z., P.L., Y.-Y.W. and X.-S.H.; formal analysis, H.-S.L. and S.-Z.W.; investigation, H.-Y.X., X.Y., J.-Y.Z., T.L., S.-Y.L., P.-Y.X., X.-Z.H., T.Z., G.-J.Y., L.-Q.Z., P.L., Y.-Y.W. and X.-S.H.; resources, H.-Y.X., X.Y., J.-Y.Z., T.L., S.-Y.L., P.-Y.X., X.-Z.H., T.Z., G.-J.Y., L.-Q.Z., P.L., Y.-Y.W. and X.-S.H.; data curation, H.-Y.X., X.Y., J.-Y.Z., T.L., S.-Y.L., P.-Y.X., X.-Z.H., T.Z., G.-J.Y., L.-Q.Z., P.L., Y.-Y.W. and X.-S.H.; writing—original draft preparation, H.-S.L. and S.-Z.W.; writing—review and editing, H.-Y.X., H.-S.L., S.-Z.W., X.Y., J.-Y.Z., T.L., S.-Y.L., P.-Y.X., X.-Z.H., T.Z., G.-J.Y., L.-Q.Z., P.L., Y.-Y.W. and X.-S.H.; visualization, H.-S.L. and S.-Z.W.; supervision, Y.W. and P.-Y.X.; project administration, Y.W. and P.-Y.X.; funding acquisition, Y.W. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Beijing Health Promotion Association (Grant No. 2021-053-ZZ).

Institutional Review Board Statement: This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the Chinese PLA hospital and the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (NO. 18-070/1648; NO. 20-232/2428).
Informed Consent Statement: Informed consent was obtained from the prospectively enrolled patients in the AFANDA cohort, while it was waived for the retrospectively enrolled ones.

Data Availability Statement: The dataset(s) supporting the conclusions of this article is(are) included within the article (and its additional file(s)).

Acknowledgments: We are grateful for the cases provided by the publicly available Afatinib Uncommon EGFR Mutations Database, as well as to the original authors who provided them. All content on the public Afatinib Uncommon EGFR Mutations Database (https://www.uncommonegfrmutations.com/results/search) is the property of the Boehringer Ingelheim group of companies and is protected by copyright. Permission to use documents (such as white papers, news releases, datasheets, and FAQs) from this website is granted, provided that (1) this notice appears in all copies and that, in particular, both the copyright notice and this permission notice appear, (2) use of such documents from this site is for informational, media, and non-commercial or personal use only, and that the documents will not be copied or posted on any network computer or broadcast in commercial media, and (3) no modifications of any documents are made.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Barta, J.A.; Powell, C.A.; Wisnivesky, J.P. Global Epidemiology of Lung Cancer. Ann. Glob. Health 2019, 85, 8. [CrossRef]
2. Deligiosi, M.V.; Trafalis, D.T. Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: An intriguing perspective. Expert Opin. Biol. Ther. 2020, 20, 1331–1346. [CrossRef]
3. Remon, J.; Hendriks, L.E.L.; Cardona, A.F.; Besse, B. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. Cancer Treat. Rev. 2020, 90, 102105. [CrossRef]
4. Huang, C.H.; Ju, J.S.; Chiu, T.H.; Huang, A.C.; Tung, P.H.; Wang, C.C.; Liu, C.Y.; Chung, F.T.; Fang, Y.F.; Guo, Y.K.; et al. Afatinib treatment in a large real-world cohort of non-small cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation. Int. J. Cancer 2021, 150, 626–635. [CrossRef]
5. Wu, J.Y.; Yu, C.J.; Chang, Y.C.; Yang, C.H.; Shih, J.Y.; Yang, P.C. Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2011, 17, 3812–3821. [CrossRef]
6. Baek, J.H.; Sun, J.M.; Min, Y.J.; Cho, E.K.; Cho, B.C.; Kim, J.H.; Ahn, M.J.; Park, K. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea. Lung Cancer 2015, 87, 148–154. [CrossRef]
7. Kuiper, J.L.; Hashemi, S.M.; Thunnissen, E.; Snijders, P.J.; Grünberg, K.; Bloemena, E.; Sie, D.; Postmus, P.E.; Heideman, D.A.; Smit, E.F. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Br. J. Cancer 2016, 115, 1504–1512. [CrossRef]
8. Chiu, C.-H.; Yang, C.-T.; Shih, J.-Y.; Huang, M.-S.; Su, W.-C.; Lai, R.-S.; Wang, C.-C.; Hsiao, S.-H.; Lin, Y.-C.; Ho, C.-L.; et al. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. J. Thorac. Oncol. 2015, 10, 793–799. [CrossRef]
9. Yang, J.C.; Sequist, L.V.; Geater, S.L.; Tai, C.M.; Mok, T.S.; Schuler, M.; Yamamoto, N.; Yu, C.J.; Ou, S.H.; Zhou, C.; et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015, 16, 830–838. [CrossRef]
10. Yang, J.C.H.; Schuler, M.; Popat, S.; Miura, S.; Heeeke, S.; Park, K.; Märtén, A.; Kim, E.S. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J. Thorac. Oncol. 2020, 15, 803–815. [CrossRef]
38. Paz-Ares, L.; Tan, E.H.; O’Byrne, K.; Zhang, L.; Hirsh, V.; Boyer, M.; Yang, J.C.; Mok, T.; Lee, K.H.; Lu, S.; et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial. Ann. Oncol. 2017, 28, 270-277. [CrossRef]

39. Park, K.; Cho, B.C.; Kim, D.-W.; Ahn, M.-J.; Lee, S.-Y.; Gernhardt, D.; Taylor, I.; Campbell, A.K.; Zhang, H.; Giri, N.; et al. Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: A phase I/II trial. J. Thorac. Oncol. 2014, 9, 1523-1531. [CrossRef]

40. Morita, A.; Hosokawa, S.; Yamada, K.; Umeh, T.; Kano, H.; Kayatani, H.; Shiojiri, M.; Sakugawa, M.; Bessho, A. Dacomitinib as a retreatment for advanced non-small cell lung cancer patient with an uncommon EGFR mutation. Thorac. Cancer 2021, 12, 1248–1251. [CrossRef]

41. Choudhury, N.J.; Makhnin, A.; Tobi, Y.Y.; Daly, R.M.; Preeshagul, I.R.; Iqbal, A.N.; Ahn, L.S.; Hayes, S.A.; Heller, G.; Kris, M.G.; et al. Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib. JCO Precis. Oncol. 2021, 5. [CrossRef] [PubMed]

42. Biswas, B.; Ganguly, S.; Ghosh, J.; Roy, S.; Bakshi, R.; Dabkara, D. Real-world experience of dacomitinib in EGFR mutated advanced NSCLC: A single center experience from India. J. Clin. Oncol. 2021, 39, e21043. [CrossRef]

43. Jänne, P.A.; Ou, S.I.; Kim, D.W.; Oxnard, G.R.; Martins, R.; Kris, M.G.; Dunphy, E.; Nishio, M.; O’Connell, J.; Paweletz, C.; et al. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: A multicentre, open-label, phase 2 trial. Lancet Oncol. 2014, 15, 1433–1441. [CrossRef]